Harnessing CRISPR interference to resensitize laboratory strains and clinical isolates to last resort antibiotics.

ABSTRACT: The global race against antimicrobial resistance requires novel antimicrobials that are not only effective in killing specific bacteria, but also minimize the emergence of new resistances. Recently, CRISPR/Cas-based antimicrobials were proposed to address killing specificity with encouraging results. However, the emergence of target sequence mutations triggered by Cas-cleavage was identified as an escape strategy, posing the risk of generating new antibiotic-resistance gene (ARG) variants. Here, we evaluated an antibiotic re-sensitization strategy based on CRISPR interference (CRISPRi), which inhibits gene expression without damaging target DNA. The resistance to four antibiotics, including last resort drugs, was significantly reduced by individual and multi-gene targeting of ARGs in low-

SUBMITTER: Frusteri Chiacchiera A 

PROVIDER: S-EPMC11696610 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature